Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
02:32pm, Thursday, 17'th Oct 2024
HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
A Market Crash Could Ruin Baby Boomers: 5 Safe High-Yield Dividend Stocks and Advice
07:16am, Wednesday, 16'th Oct 2024
24/7 Wall St. Insights The 2025 Social Security COLA will be only 2.5%.
3 Dividend Stocks for October 2024
12:30pm, Sunday, 13'th Oct 2024
#Morningstar #VerizonStock #DividendStocks These three dividend payers have an average yield of more than 4.5%. 00:00 Introduction 00:10 Bristol-Myers Squibb BMY 00:45 Polaris PII 01:04 Verizon VZ
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Friday, 11'th Oct 2024
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $52.20, denoting a -0.38% change from the preceding trading day.
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
02:40pm, Wednesday, 09'th Oct 2024
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
10:08am, Wednesday, 09'th Oct 2024
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon
10:30am, Sunday, 06'th Oct 2024
Frequent trading can erode gains due to transaction costs and taxes; a buy-and-hold strategy is often more effective for retail investors. Bristol Myers Squibb offers a strong dividend yield, below-av
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
06:51pm, Thursday, 03'rd Oct 2024
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo.
2 Passive-Income Stocks to Load Up On in October
06:45am, Thursday, 03'rd Oct 2024
These two dividend powerhouses are ideal choices for passive-income investors.
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
01:43pm, Monday, 30'th Sep 2024
Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
08:38am, Monday, 30'th Sep 2024
On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-c
3 Surprisingly Underrated Stocks to Buy Right Now
07:30am, Saturday, 28'th Sep 2024
Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
01:04am, Saturday, 28'th Sep 2024
Bristol-Myers Squibb's stock is poised to rise due to the FDA approval of Cobenfy, a novel antipsychotic for schizophrenia, and improved technicals. The company's $14 billion acquisition of Karuna The
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
06:00pm, Friday, 27'th Sep 2024
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
